Noramco signs AMPAC to top up API and intermediates supply

21-Mar-2018 - Last updated on 21-Mar-2018 at 13:23 GMT

GettyImages/PashaIgnatov

AMPAC Fine Chemicals will boost Noramco Inc.’s supply of active pharmaceutical ingredients and intermediates to make abuse prevention and attention deficit disorder treatments, and cannabinoids.

According to the strategic partnership agreement, AMPAC Fine Chemicals (AFC) will supply Noramco with certain US Drug Enforcement Administration (DEA) controlled substances from its manufacturing plant in Petersburg, Virginia.

The US DEA Schedule II and III drugs include substances with a high, or moderate to low potential for physical and psychological dependence, respectively.

According to Noramco, the Virginia facility will complement its in-house capabilities in Delaware to provide the extra capacity it needs to meet growing demand.

A Noramco spokesperson told us the APIs in the agreement are key for addiction treatment and abuse deterrent formulations.

“Specifically, the APIs and intermediates for Buprenorphine HC1, Naltrexone, Naltrexone HC1, and Naloxone,” we were told.

A move to cannabinoids

Traditionally an opioid API-focused firm, Noramco added cannabinoids to its portfolio last year, in response to drug industry demand.

Now both firms make intermediates and APIs for the cannabinoid family, including cannabidiol and dronabinol.